Zobrazeno 51 - 60
of 93
pro vyhledávání: '"Michael C. Cox"'
Publikováno v:
Current Drug Metabolism. 7:677-685
Despite its controversial past, thalidomide is currently under investigation for the treatment of several disease types, ranging from inflammatory conditions to cancer. The mechanism of action of thalidomide is complex and not yet fully understood, b
Publikováno v:
Expert Review of Anticancer Therapy. 5:605-611
Androgen deprivation therapy is a mainstay for the treatment of advanced prostate cancer. Hormonal therapy commonly consists of injection of gonadotropin hormone-releasing hormone agonists. Based on the need for improved convenience of administration
Publikováno v:
Current Oncology Reports. 7:215-219
Prostate cancer is the leading cause of cancer diagnosis in men and the second leading cause of cancer-related death. Androgen ablation is effective initially, and progression of disease often occurs in many patients. Although recent reports have not
Autor:
James L. Gulley, Michael C. Cox, Elizabeth Jones, Suoping Zhai, Allyson Parr, Serge Cremers, William D. Figg, Yinong Liu, Clara C. Chen, William L. Dahut, Xiaowei Yang, Seth M. Steinberg, David J. Liewehr, Philip Arlen
Publikováno v:
Journal of Urology. 173:790-796
Alendronate (AL), a potent oral bisphosphonate, blocks the secretion of matrix metalloproteinase-2 and the establishment of bone metastases in animal models. Ketoconazole (KT) has demonstrated activity in androgen independent prostate cancer (AIPC).
Autor:
W. Marston Linehan, Eddie Reed, W. Van Bingham, Michael C. Cox, Oliver Sartor, Michael E. Franks, James A. Eastham, William D. Figg, David Venzon, Paul H. Duray
Publikováno v:
World Journal of Urology. 22:425-430
Although multiple studies have addressed the prognostic importance of tumor differentiation in patients with clinically localized prostate cancer, few data are available in patients with metastatic disease. We evaluated and compared survival data in
Publikováno v:
Journal of Clinical Oncology. 22:2489-2503
PurposeInterest in the use of herbal products has grown dramatically in the Western world. Recent estimates suggest an overall prevalence for herbal preparation use of 13% to 63% among cancer patients. With the narrow therapeutic range associated wit
Publikováno v:
Pharmacotherapy. 24:690-693
Autor:
Leo Mascarenhas, Alberto S. Pappo, Steven G. DuBois, Douglas S. Hawkins, Scott Cruickshank, Michael C. Cox, Noah Federman, Mark Reynolds, Brian Turpin, Theodore W. Laetsch, Steven J. Smith, Ramamoorthy Nagasubramanian
Publikováno v:
Journal of Clinical Oncology. 35:10510-10510
10510 Background: Larotrectinib is the first selective small-molecule inhibitor of TRKA, B, and C in clinical development. Data from the adult phase I trial demonstrate prolonged responses in patients (pts) with TRK fusions and a favorable tolerabili
Autor:
Steven G. DuBois, Brian Turpin, Alexander Drilon, Ulrik Lassen, Marcia S. Brose, Douglas S. Hawkins, Nora Ku, Theodore W. Laetsch, Shivaani Kummar, Valentina Boni, George D. Demetri, Wafik S. El-Deiry, Scott Cruickshank, Michael C. Cox, Anna F. Farago, David M. Hyman, Afshin Dowlati, Alberto S. Pappo, Ramamoorthy Nagasubramanian, David S. Hong
Publikováno v:
Journal of Clinical Oncology. 35:LBA2501-LBA2501
LBA2501 Background: Larotrectinib is the first selective small-molecule pan-TRK inhibitor. TRK fusions appear oncogenic independent of tumor lineage, are widely distributed across cancers, and affect all ages. We present an integrated dataset from 3
Autor:
N. Nanda, James J. Lee, David S. Hong, S. Smith, Howard A. Burris, S. Cruikshank, Michael C. Cox, Robert C. Doebele, A. Dowlati, Marcia S. Brose, Alice T. Shaw, Michelle Taylor, Anna F. Farago, Todd M. Bauer
Publikováno v:
European Journal of Cancer. 72:S148